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Abstract 
• Next-generation sequencing of both DNA and RNA represents a second revolution in equine 
genetics following publication of the equine genome sequence. 
• Technological advancements have resulted in a wide selection of next-generation sequencing 
platforms capable of completing small targeted experiments or resequencing complete genomes. 
• DNA and RNA sequencing have applications in clinical and research environments. 
• Standards for the validation and sharing of next-generation sequencing data are critical for the 
widespread application of the technology and applications discussed herein. 
• As researchers and clinicians develop a better understanding of how genetic variation and phe-
notypic variation are linked, next-generation sequencing could help pave the way to personalized 
and precision management of horses. 
 




The sequencing and assembly of a reference genome for the horse has been revolutionary 
for investigation of horse health and performance. Since its publication,1 the reference genome 
has enhanced and accelerated genetic research in the horse, led to the development of new 
ideas regarding management and precision medicine, and has led to the development of 
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powerful tools that increased the scope and resolution of understanding the genetic un-
derpinnings of equine physiology and disease pathology.2,3 The insights gained into equine 
health as a result of these new tools and ideas are expertly reviewed in the accompanying 
articles of this special issue. The advent and application of next-generation sequencing 
(NGS) methods represent a second revolution for the study of equine genetics, enabling 
researchers to exploit and explore the information encoded in the equine genome through 
their experiments. NGS has also improved the ability of researchers to translate their dis-
coveries into clinically relevant applications. This article provides an overview of the his-
tory and development of NGS, details some of the available sequencing platforms, and 
describes currently available applications in the context of both discovery and clinical set-




Figure 1. Visual summary of the key points for NGS application in the horse in both dis-
covery and clinical settings. 
 
Building Genomic Resources for the Horse 
 
The use of DNA sequencing to investigate the underlying cause of heritable conditions in 
the horse dates to the early 1990s. At that time, before the development of an equine refer-
ence genome, genetic studies relied on the use of genomic information from other species 
to inform the investigation for important traits of the horse. Major successes using that 
approach include the identification of a missense mutation causative of hyperkalemic pe-
riodic paralysis in the quarter horse4 and lethal white overo syndrome in American Paint 
Horses.5 In 1995, the scientific communities’ focus on generating genomic tools specific to 
the horse incited the formation of the Horse Genome Project. Through this collaboration, 
intentional and international partnerships were built across academic and industry insti-
tutions, resulting in the generation of comparative, linkage, and radiation hybrid maps of 
the equine genome (reviewed in Chowdhary6). 
The most notable advancement for equine genomics thus far dates to 2006 when the 
National Human Genome Research Institute of the National Institutes of Health identified 
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the horse as a species of priority for genome sequence assembly efforts. In 2007, a draft 
reference equine genome was completed.1 This reference genome, named EquCab2, was 
generated with sequencing data from a single thoroughbred mare, Twilight, resulting in 
an assembly with approximately 6.8-fold coverage. The assembly of these data was com-
plemented by additional sequence information (bacterial artificial chromosome sequenc-
ing) of Twilight’s half-brother, Bravo. At the time, the accuracy of Sanger sequencing and 
availability of linkage and physical maps of the genome resulted in EquCab2 being one of 
the highest-quality reference genomes of any agricultural species. The genome was esti-
mated to be 2.7 billion base pairs (bp), with more than 20,000 protein-coding genes anno-
tated in the initial effort.1 This resource served as the basis for the development of genomic 
tools and discovery for the following decade with assays to detect genomic and tran-
scriptomic variation in the horse2,3,7–9 anchored in EquCab2. 
In 2018, a new reference assembly, still based primarily on the sequence of Twilight, 
was released.10 This improved reference genome, EquCab3, was the product of new tech-
nologies for sequencing of longer reads, helping to characterize repetitive regions of the 
genome. The EquCab3 assembly also incorporates data generated by methods that use 
structural proximity of sequences to help build continuity (Chicago11 and HiC12 libraries). 
Compared with EquCab2, EquCab3 has 90% fewer gaps, better coverage of GC-rich re-
gions, which often include gene promoters; and more complete coverage of the transcrip-
tome.10 EquCab3 now serves at the primary reference genome assembly for the horse and 
should be used for the analysis of future sequence data. It continues to be improved 
through additional efforts to annotate not only protein-coding regions, but noncoding 
RNA as well as regulatory features.13 Both EquCab2 and EquCab3 are available through 
the National Center for Biotechnology Information (NCBI), Ensembl, and University of 




The driving force behind many of the developments in equine genetics, including but not 
limited to the reference genome sequence, has been ever-improving and increasingly ac-
cessible DNA sequencing technology. The advancing technologies are generally grouped 
into distinct generations by the scientific community to recognize the transformational im-
pact they have had on the understanding of genetics. The history and impact of each gen-
eration of sequencing technology have been reviewed in detail.14,15 This article presents a 
brief overview of each sequencing generation and specifically how it has or can affect stud-
ies of the equine genome related to animal health. 
The method used to generate the data for assembly of EquCab2, data that were also 
used for EquCab3, was Sanger sequencing, first published in 1977.16 Still used for projects 
concerning a single gene or small portion of DNA, Sanger sequencing produces a high-
quality sequence in long fragments. Sanger sequencing relies on the selective incorporation 
of dideoxy nucleotides during elongation of the nascent DNA strand during in vitro DNA 
replication. Fragments are then visualized using an electrophoretic system to identify each 
nucleotide in sequence. This method, which can generate sequence fragments of about 800 
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bp, may be limited in throughput but remains the gold standard for accuracy (reviewed in 
Shendure and Ji17). 
As researchers began to work to develop reference genome assemblies, increasing the 
throughput of sequencing technologies became a priority. The motivation behind the rapidly 
evolving technology was to improve access by increasing accuracy and data-generating 
capacity while at the same time decreasing costs. NGS technologies were designed to in-
crease the rate by which data were generated through platforms that allowed for multiple 
sequence reads to be collected at 1 time and also by coupling the inclusion of labeled nu-
cleotides with the step of reading their identity. Next-generation, or massively parallel, 
sequencing, therefore, had an advantage in its ability to generate a significantly greater 
amount of sequence data at 1 time, although read length was compromised compared with 
that possible with Sanger sequencing. In the past 10 to 15 years, NGS has become a stand-
ard method used in questions regarding the evolution of the species, for discovery of var-
iation associated with phenotypes of interest, for the identification of diversity among 




As sequencing technologies have advanced, sequencing platforms available to generate 
data have expanded at an astounding rate. Ten years ago, there were only a few types of 
instruments available; these were expensive and required significant laboratory resources 
to deploy. At present, there is a wide selection of instruments tailored to generate any-
where from a small amount of targeted sequence data to massive amounts of sequence 
data capable of characterizing an entire genome in a single experiment. The various plat-
forms use different types of chemistry; those differences have been previously reviewed.18,19 
Now there is an NGS platform for most any job. As this technology continues to become 
more accessible and manageable, it enhances the opportunities for sequencing and its 
many applications to find their way into clinical practice. 
The available NGS platforms can be classified into 3 main groups: production, bench-
top, and portable systems. The choice of which platform to use depends on several varia-
bles of interest, the overall throughput needed, the accuracy of base calls, read length, 
speed of data generation, and budget. Each platform category is described briefly in the 
following paragraphs and is summarized in Table 1. 
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Table 1. Comparison of production, benchtop, and portable next-generation sequencing platforms 
 System Scale 
 Production  Benchtop  Portable 
Descriptors Minimum Maximum  Minimum Maximum  Minimum Maximum 
Sequence output 7.5 Gbp 6 Tbp  1.2 Gbp 150 Gbp  1.8 Gbp 30 Gbp 
Read output 0.5 M 20 B  4 M 400 M  7 M 12 M 
Read length 50 bp 1 KB+  50 bp 1 KB+  — 10 Kb+ 
Platforms Illumina HiSeq 4000 
Illumina HiSeqX 
Illumina NovaSeq 6000 
PacBio Sequel/Sequel II 
Oxford Nanopore 
   PromethION 
 Illumina MiSeq 
Illumina NextSeq 
Illumina iSeq 100 
ThermoFisher Ion 
   S5/S5 XL 
Oxford Nanopore 
   GridION 
 Oxford Nanopore 
   MinION 
Oxford Nanopore 
   Flongle 
Oxford Nanopore 
   SmidgION 
Applications Whole-genome 





   interactions 
Transcriptome 
   sequencing 
Gene expression 
   profiling 
Small RNA sequencing 
 Targeted sequencing 
Targeted expression 
   profiling 
Small genome 
   sequencing 
Small RNA sequencing 
 Small genome 
   sequencing 
Targeted sequencing 
Targeted expression 
   profiling 
Epigenetic sequencing 
 
Production systems represent the highest-throughput technology available and are tar-
geted primarily for discovery and research applications. The designation of a production 
system is derived from the idea that a researcher would need to produce a genome or 
transcriptome sequence. Systems in this category have sufficient capacity to sequence an 
entire genome in a single run (realistically many genomes given the coverage needed). 
They are almost exclusively housed in core or service facilities because of the cost to pur-
chase, deploy, and operate them. The advantage of these platforms is the output. One of 
the highest-throughput systems currently available, the Illumina NovaSeq 6000, can gen-
erate 6 Tb of sequence data or 20 billion reads in less than 2 days (https://www.illumina 
.com). This amount of data represents enough sequence to characterize the genome of 1 
horse more than 300 times. More practically, this amount of data can be used to sequence 
the genomes of 15 individual horses to coverage sufficient to confidently identify variation 
unique to an individual in a single run. Other production-level systems, such as those from 
Pacific Biosystems (https://www.pacb.com/) and Oxford Nanopore (https://nanoporetech 
.com/) Technologies, produce significantly fewer reads per run than the Illumina systems. 
Generating long-read output, the reads they produce are generally 10 to 100 times the size, 
which increases their value for the assembly of complicated genomic or transcriptomic re-
gions. However, long-read sequencing remains expensive for most purposes. At the time 
of writing, whole-genome sequencing at approximately 15 times coverage using short-read 
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technology can be generated at a core facility for approximately $500 per individual. Over-
all, these production systems increase sequencing capacity and improve accessibility for 
researchers by reducing sample costs so that NGS technology can be applied effectively to 
more research questions. 
Benchtop systems represent the category of sequencers, which literally live in a labora-
tory on the benchtop. In general, they have moderate sequencing capacity (1.2–150 Gbp 
sequence data and 4–400 million reads per run) but represent an improvement in accessi-
bility for investigators. These instruments serve smaller communities of researchers (or 
even a single laboratory) compared with the production systems. Therefore, benchtop sys-
tems often allow faster data generation because the researchers are not sharing the instru-
ment with as many other users and do not have to wait as long to use the machine. 
Examples of these include the Illumina MiSeq, iSeq 100, the ThermoFisher Ion Gene Studio 
S5, and the Oxford Nanopore GridION. Benchtop systems are optimized for investigators 
who have smaller sample sizes (e.g., preliminary studies), who wish to perform transcrip-
tome analyses, which generally require lesser sequence output, or who have targeted se-
quencing objectives. These systems can also be used by those who want to use sequencing 
in clinical medicine, although the applications for such sequencing are still developing. 
Like much of technology, sequencers are becoming more efficient and are beginning to 
come in much smaller packages. Portable systems are designed to allow sequencing with-
out the requirement of the support of a full laboratory. Examples of these systems are cur-
rently available from Oxford Nanopore and include the MinION and SmidgION (a small-
capacity sequencer that can be operated with a smartphone). The amount of data generated 
is impressive but generally lower than either the benchtop or production systems. Both 
systems are supported by equally portable sample preparation and analysis tools. Possible 
applications of these mobile systems include stall-side diagnoses of an infectious pathogen 
or DNA verification of an individual’s identity. Analyses can be conducted in a short 




Just as the number and type of available sequencers have proliferated, so too have the 
types of data produced. The primary distinction of sequence data is the length of reads 
generated by the sequencing instrument. There are 2 main categories for NGS data: short 
and long reads. Short sequence reads (short reads) are usually shorter than 500 bp in 
length, whereas long sequence reads (long reads) exceed 1000 bp.20 Sanger sequencing 
reads are between these 2 classifications. 
Short-read sequence is the most common type of NGS data reported in the literature. 
The main advantage of short-read sequencing is that a single instrument can produce large 
amounts of data with high-quality base calls in 1 run (see Table 1). This ability gives re-
searchers/clinicians options for their sequencing experiments: they can generate high lev-
els of coverage on a few individual samples to support identification of sequence variants 
in DNA and characterization of gene expression (Table 2), or they can pool samples to 
efficiently and cost-effectively generate data for large sample sets. Short reads can be clas-
sified as either single-end or paired-end. This designation refers to whether sequence was 
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generated from both or just 1 end of the captured DNA fragments. Single-end short reads 
are valuable for rapid and inexpensive characterization of DNA sequence or gene expres-
sion. However, their use is limited for the characterization of complex sequence regions 
such as sequence repeats or alternative splicing. This limitation results from ambiguity in 
aligning the single-end read back to a reference genome. The advantage of paired-end 
reads is that sequence from both ends of a DNA fragment of known length is generated. 
Then, information from both ends of the read can be used in parallel, which enhances the 
strategies used to address characterization of complex sequences. Paired-end reads, which 
align to the reference genome at a distance (between the reads) less than or greater to what 
was expected, can indicate the presence of a sequence variant such as an insertion or dele-
tion, or, in the case of transcriptome data, can reveal patterns of alternative splicing. Figure 
2 shows both single-end and paired-end short reads and the application of those reads to 
the characterization of DNA and RNA sequences. 
 
Table 2. Summary of various next-generation sequencing application categories, including the 
type of variants it is possible to assay and how much sequence data are required 
Target Category Application/Detection Coverage/Sequence Required 




De novo assembly 
SNPs, INDELs, CNVs, 
   genotyping 
SNPs 
ChIP, SNPs, chromosome 
   conformation 
Bisulfite 
SNPs, INDELs, CNVs, 
   genotyping 
10× to 60× coverage 
100× coverage 
15–100 million reads 
15–30 million reads 
140× coverage 
RNA Transcriptome sequencing 
Targeted Sequencing 
De novo assembly 
Differential expression, small 
   RNAs, alternative splicing 
CLIP, transcript panels, tag 
   capture 
Differential expression, small 
   RNAs, alternative splicing 
10–100 million reads 
5–40 million reads 
> 100 million reads 
Abbreviations: ChIP, chromatin immunoprecipitation; CLIP, cross-linking immunoprecipitation; CNVs, copy 
number variations; INDELs, insertions/deletions; SNPs, single nucleotide polymorphisms 
 
  




Figure 2. Various read types and read lengths and the application of those reads for DNA 
and RNA sequencing. In both cases, the reads are aligned to a reference genome (black 
rectangle) for analysis. (A) DNA sequencing: the region of the genome depicted contains 
2 copies of a repeated motif (green rectangles). Single-end short reads are aligned across 
the genome at unique locations (blue rectangles) or multiple locations (red rectangles) if they 
originated from a repeat sequence. Paired-end short reads (yellow rectangles joined by 
dashed lines) can help to characterize the repeat regions because they align to the repeats 
and are anchored by alignment to unique sequences. Long reads (large purple boxes) align 
uniquely to the reference genome and can be used to characterize repeat sequence because 
they span the entire region. (B) RNA sequencing: the area of the genome depicted encodes 
a protein-coding gene (green boxes connected by solid lines). Single-end short reads map to 
sequence representing the exonic regions of the gene and can be mapped with a gapped 
alignment (light blue rectangles joined by angled solid lines) representing the union of 2 exons 
by splicing. Paired-end short reads also align to the exonic regions of the gene and can be 
used to define exon order in a transcript by linking multiple exons together. Long reads 
can help determine full-length transcripts and can be used to separate overlapping tran-
script structures. 
 
Long-read sequence data are increasing in popularity for NGS experiments. The instru-
ments that generate these data generally produce fewer sequence reads per run, but the 
reads they do provide are significantly longer than those from any short-read NGS plat-
form (see Table 1). When first released, reads from these instruments averaged 1100 bp in 
length. Improvements in chemistry quickly increased the expected read length to 10,000 
bp, with some reads spanning 60,000 bp. Genome assembly and the investigation of large-
scale structural variation is aided by long-read sequencing because the long reads can 
sometimes span the length of repetitive regions of the genome, or moderately sized inser-
tions/deletions. The read length achievable has led to the preferential use of this platform 
for genome assembly and scaffolding, as was the case in the newest assembly of the equine 
genome, EquCab3.10 Long-read sequencing has also helped to resolve the structure and 
sequence of highly repetitive regions such as the equine major histocompatibility complex.21 
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Long sequence reads can also be used for annotation of alternative splicing in the tran-
scriptome because the long reads can span entire transcripts. Figure 2 shows how long 
reads can be used in both DNA and RNA sequencing (RNA-seq) applications. A common 
strategy is to combine both short-read and long-read data in a single NGS experiment to 




With production instruments now capable of producing terabytes of data each run, the 
sequencing of a horse’s entire genome is now arguably the most common use of NGS tech-
nologies. This type of sequencing can allow the identification of inherited or de novo var-
iation associated with disease. Whole-genome sequencing in the horse has enabled the 
discovery of variation that can be assayed to identify the risk of disease or for use in diag-
nosis. Some findings that resulted from the use of whole-genome sequence include mis-
sense variants causative of lavender foal syndrome,22 immune-mediated myositis,23 the 
identification of a locus associated with risk for squamous cell carcinoma in Haflingers,24 
a nonsense mutation associated with hydrocephalus in Friesians,25 a splice-site mutation 
in Friesian horses with dwarfism,26 and a large deletion associated with occipitoatlantoax-
ial malformation.27 A practical alternative to whole-genome sequencing can be sequencing 
of only the exome, the regions of the genome that code for the exons of protein-coding 
genes. This approach requires that the exonic sequence is captured (either in solution or 
on an array) to prepare the DNA for sequencing. Because the region to be sequenced is 
reduced relative to the whole genome, this approach can enable a researcher to generate 
sequence from a larger number of individuals. The primary limitation in horses is the avail-
ability of capture technology. Exome sequencing has been used in the horse to identify 
variants relative to racing performance in quarter horses.28 In each of these examples, the 
sequence generated was aligned to the reference genome and variants differing between 
affected horses and the reference sequence, or compared with healthy controls, were iden-
tified. As part of this process, after variants that either fit the hypothesized mode of inher-
itance or are found in candidate genes are identified, the possible function of each can be 
predicted using the genome annotation. In cases where genes may not be annotated, the 
region can be aligned to orthologous loci of other species. The impact of genomic variants 
on gene expression can also be assayed through RNA sequencing of the appropriate tis-
sues. 
The process of sequencing of the transcriptome (any portion of the DNA actively being 
transcribed into RNA at the time the tissue is sampled) is similar to that of sequencing 
DNA. The exception is an initial reverse transcription step, through which the isolated 
RNA is converted to double-stranded, copy DNA. The library preparation method used 
for RNA-seq depends on the question at hand. Poly-A+ selected libraries capture most mes-
senger RNA and some long noncoding RNA, as long as a poly-A tail is present on the 
transcript. Poly-A+ library preparation and paired-end sequencing are the most common 
means to assess the expression of protein-coding loci. Differential expression can also be 
assayed using 3′ tag-seq (Quantseq; Lexogen, Greenland, NH), a method in which libraries 
are created for only the 3′ end of each RNA molecule present in the sample. Tag-seq does 
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not allow the identification of gene isoforms, but, by focusing sequencing efforts on only 
the terminal end of each transcript, differential expression analyses require significantly 
lower sequencing depth (~6 million reads per sample)29,30 using single-end reads, therefore 
reducing overall cost. As in whole-genome sequencing, reads from RNA-seq are mapped 
to the reference genome or, in some cases, the transcriptome. In the horse, RNAseq data 
have been used to develop and improve gene annotation.31–34 The relative abundance of 
each transcript can then be quantified using the available gene annotation and compared 
between treatments or disease states.35–39 The sequencing of mRNA through poly-A+ selec-
tion not only allows the quantification of each transcript but can provide insight into splice-
site variation. Further, RNA libraries are often stranded, meaning the sequence generated 
distinguishes the strand of DNA from which the transcript was derived. This technique is 
a powerful method to identify and distinguish antisense transcripts. The advent of long-
read technology can also be applied to studies of the transcriptome. Iso-seq is the use of 
PacBio sequencing, enabling the profiling of full-length RNA transcripts.40 This methodology 
reduces 3′ sequencing bias, which is common in poly-A+ library preparation, and is a pow-
erful means to annotate genomes and identify variation in codon usage. However, as a long-
read technology, Iso-seq is thus far too expensive for most clinical investigations. In con-
trast, Poly-A+ library preparation neglects sequencing of small RNAs such as microRNAs, 
which can be assayed with a special, small RNA library preparation method. MicroRNAs 
are small (21–25 nucleotides) RNA fragments encoded by the animal’s genome. Although 
they do not function to create proteins, they can bind to and silence the expression of protein-
coding genes; therefore, their activity in posttranscriptional modification can significantly 
affect genome function.41 In horses, microRNA profiles have been proposed as useful bio-
markers for infection42 or other disorders.43,44 
In addition to the identification of genomic variants and the transcript expression, NGS 
can be used to understand chemical modifications to the DNA, such as methylation, or to 
identify regions of the genome interacting with protein. DNA methylation, a chemical 
modification of cytosine to 5-methylcytosine, is a common epigenetic mechanism involved 
in silencing gene expression.45 Although the inheritance of some epigenetic modifications, 
such as DNA methylation, is not completely understood, like RNA-seq, examining methy-
lation patterns can help to understand differences in gene regulation and expression be-
tween diseased and healthy individuals. Similar to chromatin immunoprecipitation (ChIP; 
discussed later), genome-wide methylation can be assayed by using antibodies to precipi-
tate DNA having 5-methylcytosine modifications; that DNA is then sequenced on a next-
generation platform (MeDIP-seq).46 To the authors’ knowledge, this method has not yet been 
applied in a case of equine disease research; however, this technique has been used to char-
acterize changes in genomic methylation in equine skeletal muscle caused by exercise.47,48 
ChIP is a method by which regions of the DNA involved in an interaction with protein 
are isolated.49 Those regions of DNA can then be sequenced using standard next-generation 
methodology (ChIP-seq), and the resulting DNA fragments aligned to the reference genome 
to identify genomic regions involved in the interaction. Similarly, cross-linking immuno-
precipitation (CLIP) is a method that enables the isolation of RNA transcripts specifically 
interacting with a protein.50 The captured transcripts can be sequenced (CLIP-seq) to iden-
tify regulatory aspects of gene expression. Sequence variants in the regions of interaction 
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can alter binding efficiency and thus function. In addition, alteration in protein-DNA or 
protein-RNA interactions can uncover functional information regarding molecular mech-
anisms of disease. Therefore, these methods can be used to investigate both the functional 
significance of genomic variation as well as to identify alterations in genome activity and 
sequence composition associated with a treatment or disease. Of note, as is the case in tran-
scriptome sequencing, these methods of capturing information on genome function only 
reveal information about the genome’s activity within the tissue or cell population sampled 
at time of sampling. 
 
Data Generation and Handling 
 
For most any platform, the process of sequencing is similar. The general workflow of an 
NGS experiment is presented in Figure 3. The goals for interpretation and application of 
the data generated can result in alterations of this general approach. The sample necessary 
depends on the question at hand. For gene expression, RNA must be isolated from a tissue 
relevant to the phenotype of interest. Because RNA is relatively unstable, care has to be 
taken to either preserve the sample in an RNA-stabilization solution (e.g., RNAlater, 
Sigma-Aldrich, St Louis, Missouri; DNA/RNA Shield, Zymo Research, Irvine, California) 
or the tissue must be flash-frozen immediately after collection until processing. ChIP data 
can also be derived from a flash-frozen sample or from samples subjected to a cross-linking 
protocol, commonly performed with formaldehyde, at the time of collection. If the goal is 
to identify genomic variation, genomic DNA must first be isolated from a sample of the 
individual. Blood and tissue are commonly used samples for DNA isolation, although hair 
follicles can also produce adequate DNA for sequencing of target genes or the whole ge-
nome. The isolated DNA is hydrolyzed or sheared to create fragments of similar size and 
is processed for library preparation. Methods for library preparation are conceptually sim-
ilar, although there are platformspecific processes to make the input nucleic acid ready for 
sequencing on a particular instrument. Barcode sequences can be included and allow in-




Figure 3. General workflow of an NGS experiment. 
 
The general features of NGS data analysis are similar regardless of the platform used 
to generate the data (Fig. 4). The data received from most sequencing methods are in the 
form of fastq files. These files encode both the sequence identity of each read as well as an 
associated quality metric. Data processing then involves an initial step of quality control 
where any adapter sequences necessary for library preparation are removed, and the 
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sequence is also trimmed to eliminate base calls that do not meet a designated quality 
threshold. It is standard for the 3′ end of each read to be of lesser quality than the 5′ end, 
and thus much of the trimming occurs on this portion of the read. If a paired-end library 
is sequenced, it is important that the data from the 2 ends of each pair remain associated; 
if 1 read is completely removed because of poor quality, its paired read must also be re-
moved from the dataset. Once the data are preprocessed for quality control, the reads are 
aligned with the equine reference genome, or possibly the transcriptome (in the case of 
RNA-seq efforts). This process is computationally expensive and, depending on available 
computing resources and amount of data being processed, it could take days to weeks. 
However, the aligned reads (in bam files) can be visualized in software such as the Inte-




Figure 4. General features of NGS data analysis. CNV, copy number variation; INDEL, 
insertion/deletion; SNPs, single nucleotide polymorphisms. 
 
Once the sequencing reads are aligned, variants within the newly sequenced individual 
and between it and the reference genome can be identified. Variant calling identifies single 
nucleotide polymorphisms (SNPs), insertions/deletions, or structural variation that differ 
between each individual and the reference genome, within an individual (i.e., heterozy-
gous sites), or between study individuals. A variety of variant calling software is available 
and has been reviewed elsewhere.55,56 The choice of a variant caller depends to some extent 
on the question asked (e.g., rare variant identification vs. population frequency). In addi-
tion to the selection of variant calling software, the quality of the output also depends on 
the depth of sequence coverage, sequence quality, and ability to filter false-positive signals. 
Once variants are identified, the genome annotation provides a means to predict the func-
tional impact (e.g., nonsynonymous mutation or splice-site variant) of each. For cases with 
apparent simple inheritance, several databases exist to help identify candidate genes, or 
genes previously associated with similar phenotypes. Online Mendelian Inheritance in 
Man (OMIM; https://www.omim.org/), and Online Mendelian Inheritance in Animals (OMIA; 
https://omia.org/home/) provide information on thousands of known mendelian traits. 
Previously annotated variants and quantitative trait loci (loci associated with complex dis-
ease) are also often cataloged and can serve as valuable resources when investigating pu-
tative functional variation; these are available in databases such as the European Variation 
Archive (https://www.ebi.ac.uk/eva/). However, not all variants or genes with an essential 
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physiologic function are annotated as such. In contrast, not all loci computationally pre-
dicted or modeled to affect gene or protein function necessarily do so. Validation of func-
tion of a variant requires significant subsequent work beyond their discovery. 
For transcriptomic data, variants can be called in a manner similar to that used for 
whole-genome sequencing. However, the purpose of RNA-seq is often not to identify var-
iation but altered expression of gene expression between affected versus unaffected tis-
sues. Differential expression analyses are conducted based on the quantification of reads 
observed per transcript. Data must first be normalized to account for differences in se-
quencing depth, and, depending on the method used, analyses may also consider tran-
script length. Reviews of methods for quantification and differential expression analyses 
of RNA-seq data outline the statistical models used and assumptions underlying each ap-
proach.57,58 Transcriptomic data are often used to investigate the function of putative caus-
ative variants or to identify gene pathways associated with disease, such as in the case of 
stationary night blindness of Appaloosas35 and Arabian cerebellar abiotrophy.59 
 
Validation of Results 
 
Even though NGS is becoming common, there are currently no standards set forth by the 
veterinary industry on the interpretation or use of DNA sequencing or RNA-seq data. 
Therefore, in the use of genetic or genomic information for equine management the onus 
is on researchers, clinicians, owners, or other end users to evaluate the process by which 
the data were discovered and validated. In human medicine, various interest groups, such 
as the Next-Generation Sequencing: Standardization of Clinical testing II informatics 
workgroup60 and the American College of Medical Genetics and Genomics,61 have worked 
to address the means to ensure that rigorous standards of variant discovery and validation 
are met. Some of the principles put in place by these entities include outlining a vocabulary 
useful to classify variant function and assist clinicians in using information regarding ge-
netic tests in practice.60,61 Another idea shared by both groups emphasizes that variant 
function and predictive ability need to be validated in individuals unique to those used in 
the discovery process and the variant frequency within the population (e.g., breed in the 
case of horses) should be described. Toward a similar goal of standardizing how genomics 
research is implemented, validated, and applied, the international equine genomic re-
search community recently put forth a “Consensus Statement on the Translation and Ap-
plication of Genomics in the Equine Industry” (Havemeyer Principles 2019: https://horse 
genomeworkshop.com/values).62 In this statement, the researchers acknowledge that ge-
nomics and discovery using NGS holds significant promise to improve equine well-being. 
However, with the complexity of disease and of genome function, the community agreed 
the most significant benefit of genomics to the horse lies in discovery that encompasses 
several key elements. These elements include ensuring that genomic research is reproduc-
ible and peer reviewed, ethical, and performed and communicated with transparency. As 
the use of NGS increases, these guidelines will need to become more clearly defined be-
cause, although the potential for genomics to improve equine health and well-being is un-
deniable, its successful application also depends on the rigor of the research behind the 
discoveries. 





The degree of advancement of genomic tools for researchers and clinicians in the past 10 
years has been tremendous. The accelerated rate of discovery is likely to continue, and, 
with decreasing costs of NGS, the use of this method in the diagnosis, prevention, and 
management of disease is likely to become common practice. As researchers build a better 
understanding of how genetic variation alters an individual’s ability to respond to treat-
ment or optimize performance, the idea of personalized or precision management for horses 
is far reaching. In addition, a greater understanding of genomic relationships among indi-
viduals, as well as how genomic variation contributes to complex phenotypes such as dis-
ease, lends itself to use in genomic selection, or the incorporation of genomic information 
with phenotype data to predict an animal’s breeding value for a trait or traits of interest. 
The improved understanding of genome function and disease susceptibility supported by 
the application of NGS can lead to better horse health and welfare. 
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